Table 1.

Baseline characteristics of patients enrolled in observational studies on left atrial appendage occlusion that reported observed versus expected stroke events

Baseline characteristics	n (%), Mean ± SD
Total number of studies	29
Total number of patients	11,071
Age (years)	74.0 ± 8.7
Men	6,597 (60%)
Type of atrial fibrillation
Paroxysmal	1,804(16%)
Non-paroxysmal	9,267 (84%)
Hypertension	7,659 (69%)
Diabetes mellitus	2,681 (24%)
Prior stroke/transient ischemic attack	3,395 (31%)
Peripheral vascular disease	1,199(11%)
Congestive heart failure	1,845 (17%)
Mean CHA2DS2-VASc Score	4.22±1.48
Mean HASBLED Score	3.04±1.16
Left appendage occlusion device
Watchman	5,579 (50%)
Amplatzer cardiac plug	2,332(21%)
Amulet	1,724(16%)
Amplatzer cardiac plug /amulet	1,436(13%)
Procedural success	10,775 (97%)
Antithrombotic therapy at discharge
Oran anticoagulant	2,610 (23%)
Warfarin	1,512(58%)
Nonvitamin K antagonist oral anticoagulant	450 (17%)
Not specified (Warfarin/NOAC)	648 (25%)
Antiplatelet	7,144(65%)
Dual antiplatlets	5,097 (72%)
Single antiplatelet	1,151 (16%)
Not specified (SAPT/DAPT)	896 (12%)
Not reported/none/other	1,317(12%)

DAPT = dual anti-platelet therapy; NOAC = nonvitamin K antagonist oral anticoagulant; SAPT = single anti-platelet therapy.